Rich Pharmaceuticals

Rich Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Beverly Hills, California, focused on developing therapies for oncology and hematology. The company primarily targets orphan diseases with high unmet medical needs, with a lead product candidate named RP-101. RP-101 is a small molecule inhibitor of Heat shock protein 27 (Hsp27) being evaluated for the treatment of Acute Myeloid Leukemia (AML) and Hodgkin's Lymphoma. Rich Pharmaceuticals is a publicly traded entity on the OTC Pink market under the ticker symbol RCHA. The company's strategy involves advancing its clinical pipeline through strategic licensing and regulatory milestones in rare cancer indications.